Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

@article{Chico2001PhaseIS,
  title={Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.},
  author={I Chico and Min Ho Kang and Raymond C. Bergan and James Abraham and Susan Bakke and Beverly Meadows and Ann Rutt and Rob Robey and Peter M Choyke and Mar{\'i}a Merino and Barry R. Goldspiel and Tom M. C. Smith and Steven Steinberg and William D. Figg and Tito Fojo and Susan Bates},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 3},
  pages={832-42}
}
PURPOSE PSC 833 (valspodar) is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance. We conducted a phase I study of a 7-day oral administration of PSC 833 in combination with paclitaxel, administered as a 96-hour continuous infusion. PATIENTS AND METHODS Fifty patients with advanced cancer were enrolled onto the trial. PSC 833 was administered orally for 7 days, beginning 72 hours before the start of the paclitaxel infusion. Paclitaxel dose reductions… CONTINUE READING
28 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…